期刊文献+

复方苦参素注射液配合卵巢癌术后化疗的临床观察 被引量:5

Efficacy of Compound Oxymatrine Injection plus Postoperative Chemotherapy for Ovarian Carcinoma
暂未订购
导出
摘要 目的:配合临床化疗,研究复方苦参素注射液升高白细胞的作用。方法:将106例卵巢癌患者随机分为两组,观察组53例,对照组53例。观察组采用紫杉醇加卡铂化疗并加复方苦参素注射液静脉滴注;对照组采用紫杉醇加卡铂化疗。结果:对照组化疗后白细胞计数较化疗前显著下降(P<0.05);观察组白细胞较化疗前无显著差异(P>0.05);观察组化疗毒副作用较对照组轻(P<0.05)。结论:复方苦参素注射液能较好地保护卵巢癌术后化疗患者的白细胞计数不下降、减轻化疗的毒副作用。 OBJECTIVE:To evaluate the leukogenic effect of Compound Oxymatrine Injection when used in combination with chemotherapy.METHODS:106 patients with ovarian carcinoma were randomly assigned to either experimental group(n = 53) receiving Compound Oxymatrine Injection plus chemotherapy(Paclitaxel plus Carboplatin) or control group(n = 53) receiving chemotherapy(Paclitaxel plus Carboplatin) alone.RESULTS:The count of the leukocytes in the control group decreased significantly after treatment compared with baseline(P 0.05);however,no significant differences were noted for the experimental group after treatment in regard to the count of the leukocytes(P 0.05).The toxicity was milder in the experimental group than in the control group.CONCLUSION:Addition of Compound Oxymatrine Injection to chemotherapy for patients with ovarian carcinoma can effectively protect patients against decrease of the count of leukocytes and attenuate the side effect of chemotherapy.
出处 《中国医院用药评价与分析》 2010年第4期357-358,共2页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 复方苦参素注射液 卵巢癌 术后化疗 升白作用 Compound Oxymatrine Injection Ovarian carcinoma Postoperative chemotherapy Leukogenic role
  • 相关文献

参考文献7

二级参考文献26

共引文献103

同被引文献35

  • 1谢晓冬,刘永叶,郑振东,高雅玲,李京宁,郑宏柱,刘大为,单学健,邢春景.晚期恶性肿瘤骨转移患者治疗的临床研究[J].中国实用内科杂志,2005,25(2):127-129. 被引量:20
  • 2国家中医药管理局.中医病证诊断疗效标准.南京:南京大学出版社.1999.33.
  • 3孙燕,石远凯.临床肿瘤内科手册.5版.北京:人民卫生出版社,2008:476-477.
  • 4孙燕,石远凯.临床肿瘤内科手册[M].第5版,北京:人民卫生出版社,2008:711-717.
  • 5Weinberg LE,Rodriguez G, I-lurteau JA. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol, 2010,101 (4) : 334-343.
  • 6Pant AC,Diaz-Montes T,Tanner E,et al. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer. J Chemother,2010,22(4) :270-274.
  • 7Johhnson J R, William S G, Pazdur R. End points and UnitedStates food and drug administration approved of oncology drug. JClin 0nco,2003,2l: 1401.
  • 8Wellington K,Coa KL. Zoledmnic acid:a review of its use in themanagement of bone metastases and hypercalcaemia of malignan-cy. Drugs ,2003,63:417.
  • 9何欣,朱婴,黄立中.温阳散寒补气养血法对非小细胞肺癌患者外周血树突状细胞影响的研究[J].中国中医急症,2007,16(11):1308-1310. 被引量:28
  • 10PANT AC,DIAZ-MONTES T, TANNER E, et al. Correla- tion of extremedrug resistant assay results and progression- {tee survival following intraperitoneM chemothera py t'or ad vanced ovarian cancer [J]. I Chemother, 2010,22 ( 4 ) : 270- 274.

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部